Low levels of glutathione are commonly found in individuals with liver disorders such as fatty liver disease, hepatitis, or alcohol-related liver damage, making supplementation crucial in restoring liver function and overall well-being
This article covers what it is, how it works, FDA-approval status, clinical evidence, safety profile, and the upstream genetic pathway context
(3) emerging intervention strategies targeting mitochondrial metabolism, including small-molecule inhibitors, combination therapies, and translational opportunities
Tumor therapeutic strategies targeting SLC7A11 Several compounds have been identified as inhibitors of SLC7A11, including Erastin, IKE, sorafenib, DPI2, SAS, glutamate, and INF-
Three structurally different classes of compounds considered to be of particular interest as starting points for the development of small-molecule IRAP inhibitors were identified